Octreotide
/ Synthetic cyclic octapeptide analog of somatostatin; SSTR2/SSTR5 agonistALIAS · Sandostatin · Sandostatin LAR
Terms in this page you can click for a plain-English popup: , , , , , , , .
FDA-approved (Sandostatin, 1988) for acromegaly, carcinoid syndrome, and VIPoma. Long-acting release (LAR) formulation provides once-monthly dosing.
Octreotide is a synthetic cyclic octapeptide analog of somatostatin with preferential affinity for SSTR2 and SSTR5 receptors. It inhibits GH release (used in acromegaly), serotonin and vasoactive intestinal peptide secretion (used in carcinoid syndrome and VIPoma), and has broader effects on gastrointestinal hormone secretion.
Extensive clinical history since 1988 approval. Standard of care for medical therapy of acromegaly, symptomatic management of carcinoid syndrome, and hormone-secreting neuroendocrine tumors.
Common: gastrointestinal AEs (diarrhea, abdominal pain, steatorrhea), gallstone formation with chronic use (10-20% over years), glucose intolerance or hypoglycemia. Bradycardia at higher doses.
Regulatory status
- FDA status:
- FDA-approved
- Compounding:
- Not eligible for compounding (approved, not in shortage)